Published By: Mohammad Haris
Last Updated: September 22, 2023, 17:43 IST
Lupin Managing Director Nilesh Gupta said the acquisition aligns well with the company’s strategic goal to broaden presence in the Indian market.
Drug firm Lupin on Friday said it has inked a pact to acquire five drug brands from Italian firm Menarini for Rs 101 crore. The company has signed an agreement to acquire five legacy brands catering to gastroenterology, urology and anti-infective segments, the Mumbai-based company said in a statement.
The brands are Piclin (Picosulphate Sodium), Menoctyl (Otilonium Bromide), Sucramal O (Sucralfate + Oxetacaine), Pyridium (Phenazopyridine) and Distaclor (Cefaclor), it added.
Lupin has been exclusively marketing these brands in the Indian market since July 2021 under a distribution and promotion agreement with A Menarini India Pvt Ltd.
Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of over USD 4.4 billion and over 17,000 employees.
Menarini India is a 100 per cent subsidiary of Menarini Group.
Lupin Managing Director Nilesh Gupta said the acquisition aligns well with the company’s strategic goal to broaden presence in the Indian market.
“comprehensive range of products, our aim is to deliver even greater value to our stakeholders and the communities we serve,” he added.
(This story has not been edited by News18 staff and is published from a syndicated news agency feed – PTI)
छवि स्रोत: अफवाह छवि सैमसंग गैलेक्सी एस25 अल्ट्रा Samsung Galaxy S25 सीरीज अगले साल जनवरी…
छवि स्रोत: गेट्टी भारतीय हॉकी टीम भारतीय हॉकी टीम: आज के दौर में भले ही…
मैनचेस्टर सिटी के कप्तान काइल वॉकर ने खुलासा किया है कि टीम क्रिसमस के दिन…
छवि स्रोत: फ़ाइल छवि 5 संभावित फिल्में जो बॉक्स ऑफिस पर फ्लॉप रहीं 2024 बॉलीवुड…
1 में से 1 ख़ासख़बर.कॉम: सोमवार, 23 दिसंबर 2024 1:52 अपराह्न नून, । उत्तर प्रदेश…
छवि स्रोत: फ़ाइल फ़ोटो प्रतिनिधि छवि फिक्स डिपॉजिट लंबी अवधि के लिए सबसे भरोसेमंद निवेश…